company background image
2633 logo

Jacobson Pharma SEHK:2633 Stock Report

Last Price

HK$0.61

Market Cap

HK$1.2b

7D

0%

1Y

-38.4%

Updated

13 Jun, 2024

Data

Company Financials

Jacobson Pharma Corporation Limited

SEHK:2633 Stock Report

Market Cap: HK$1.2b

2633 Stock Overview

Through its subsidiaries, produces, markets, and sells generic drugs and branded healthcare products in Hong Kong, Mainland China, Macau, Singapore, and internationally.

2633 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends4/6

Jacobson Pharma Corporation Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jacobson Pharma
Historical stock prices
Current Share PriceHK$0.61
52 Week HighHK$1.08
52 Week LowHK$0.54
Beta0.45
1 Month Change1.67%
3 Month Change1.67%
1 Year Change-38.38%
3 Year Change-21.79%
5 Year Change-60.13%
Change since IPO-63.69%

Recent News & Updates

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Dec 21
Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

Nov 27
Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

Recent updates

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Dec 21
Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

Nov 27
Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jun 20
These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Nov 28
Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Sep 25
Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Sep 16
Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 28
Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Jul 14
Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?

Feb 09
Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012

Nov 29
Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012

Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Sep 24
Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Sep 16
Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

Feb 03
Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Jan 24
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Jan 11
Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Dec 27
Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

Dec 12
Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

Dec 03
Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

Shareholder Returns

2633HK PharmaceuticalsHK Market
7D0%-2.1%-2.0%
1Y-38.4%-4.6%-2.0%

Return vs Industry: 2633 underperformed the Hong Kong Pharmaceuticals industry which returned -4.6% over the past year.

Return vs Market: 2633 underperformed the Hong Kong Market which returned -2% over the past year.

Price Volatility

Is 2633's price volatile compared to industry and market?
2633 volatility
2633 Average Weekly Movement3.1%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement7.2%
10% most volatile stocks in HK Market15.4%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 2633 has not had significant price volatility in the past 3 months.

Volatility Over Time: 2633's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20161,588Derek Sumwww.jacobsonpharma.com

Jacobson Pharma Corporation Limited, through its subsidiaries, produces, markets, and sells generic drugs and branded healthcare products in Hong Kong, Mainland China, Macau, Singapore, and internationally. The company offers generic drugs for various therapeutic categories, including the respiratory, cardiovascular, central nervous system, gastrointestinal, genito-urinary, musculoskeletal, endocrine and metabolic, dermatological, anti-allergics, scar treatment, oral anti-diabetics, and anti-infective, as well as arsenic trioxide oral solutions. It also provides branded medicines; health and wellness products; and proprietary Chinese medicines, such as Po Chai pills, Ho Chai Kung, and Shiling oil, as well as Contractubex, Smartfish, Rowatanal, Oncotype DX, and AIM Atropine products.

Jacobson Pharma Corporation Limited Fundamentals Summary

How do Jacobson Pharma's earnings and revenue compare to its market cap?
2633 fundamental statistics
Market capHK$1.22b
Earnings (TTM)HK$244.99m
Revenue (TTM)HK$1.92b

5.0x

P/E Ratio

0.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2633 income statement (TTM)
RevenueHK$1.92b
Cost of RevenueHK$1.12b
Gross ProfitHK$794.44m
Other ExpensesHK$549.46m
EarningsHK$244.99m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Jun 20, 2024

Earnings per share (EPS)0.12
Gross Margin41.41%
Net Profit Margin12.77%
Debt/Equity Ratio55.6%

How did 2633 perform over the long term?

See historical performance and comparison

Dividends

8.0%

Current Dividend Yield

38%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.